A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes

被引：0
|
作者：
Andreas Andersen
Filip Krag Knop
Tina Vilsbøll
机构：
[1] University of Copenhagen,Steno Diabetes Center Copenhagen, Gentofte Hospital
[2] University of Copenhagen,Center for Clinical Metabolic Research, Gentofte Hospital
[3] University of Copenhagen,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[4] University of Copenhagen,Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences
来源：
Drugs | 2021年 / 81卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1003 / 1030
页数：27
相关论文
共 50 条
  • [41] Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
    Avgerinos, Ioannis
    Michailidis, Theodoros
    Liakos, Aris
    Karagiannis, Thomas
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 335 - 345
  • [42] Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
    Cowart, Kevin
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 478 - 485
  • [43] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide
    Lichert, Frank
    DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06)
  • [44] Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    McGuire, D. K.
    Marx, N.
    Mulvagh, S. L.
    Deanfield, J. E.
    Inzucchi, S. E.
    Pop-Busui, R.
    Mann, J. F. E.
    Emerson, S. S.
    Poulter, N. R.
    Engelmann, M. D. M.
    Ripa, M. S.
    Hovingh, G. K.
    Brown-Frandsen, K.
    Bain, S. C.
    Cavender, M. A.
    Gislum, M.
    David, J-P
    Buse, J. B.
    SOUL Study Group
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [45] Pharmacological treatment of hyperglycemia in type 2 diabetes
    Taylor, Simeon I.
    Yazdi, Zhinous Shahidzadeh
    Beitelshees, Amber L.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (02):
  • [46] Pharmacological treatment of type 2 diabetes mellitus
    Soidan, Francisco Javier Garcia
    Villanueva, Javier Riveiro
    ATENCION PRIMARIA, 2025, 57 (04):
  • [47] CLINICAL AND ECONOMIC CONSEQUENCES OF THE PHARMACOLOGICAL HYPOGLYCEMIC TREATMENT OF TYPE 2 DIABETES IN CROATIA
    Saric, T.
    Benkovic, V
    Poljicanin, T.
    Sekerija, M.
    VALUE IN HEALTH, 2010, 13 (07) : A301 - A301
  • [48] A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES" RESPOND
    Guzauskas, Gregory F.
    Hansen, Ryan N.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (08): : 1141 - 1141
  • [49] Semaglutide A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
    Chan, Mabel
    Dimitriou, Alexis
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2021, 29 (02) : 100 - 108
  • [50] Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-Oral Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
12345